NewLink Genetics Corporation (NASDAQ:NLNK) is among the top stocks that may remain in focus today as the company shares are trading 4.27% or 0.07 points lower from last closing price of $1.64, reaching $1.57 at last check. Any clue why there is so much of action in the NLNK stock? The share price has dropped in 2 of the last 5 days and is down -7.87% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -111,995 shares, and in total 174105 shares valued at $273345 were seen changing hands compared with 286100 shares valued at $469204 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the NLNK stock is near its bottom.
NewLink Genetics Corporation (NLNK) shares have notched a 3-month decline of about -7.87%, but has still advanced 7.89% year to date. By comparison, the stock sank -68.46% over the past 12 months, while it slipped -0.61% over the 1 month. The company’s market cap is around $61.19M, with its short interest ratio standing at 8.08%.
In the current trading session for NLNK, the stock witnessed two major price actions, it rose to a high of $1.64 and was down as much as $1.56 at one point. The high recorded is very low when compared to their 52-week high which is $1.28. The 52-week high is now at -71.31 distance from current price. Their recent low of $5.49 represents a 23.29% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for NLNK is $2.5, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of NewLink Genetics Corporation earned $-1.22 per share in the trailing 12 months and has a P/E ratio of -1.29. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.27 and lower compared to the sector’s average of 37.46. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. NLNK also has P/S multiple of 21.7. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 43.04x.
The company recorded an interesting insider sale transaction by the Director on Jul 10, 2018. A Securities and Exchanges Commission filings show that Ernest Talarico III sold a total of 13,806 NLNK shares that day for a sum of around $66,545. The filings show that the insider now retains 39,365 shares, currently worth $61,803. NewLink Genetics Corporation (NLNK) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded no shares in the business, which makes up 0% of 34,170 shares that were traded over a year. In the past 12 months, insiders have purchased zero shares while the seller parted with 34,170 shares.
NLNK‘s last price was down -16.53% as compared to the average trading price of 50 days recorded at $1.88 while enlarging the period to 200 trading days, the average closing price was $1.69. At present, there are 37.31 million in the total number of common shares owned by the public and among those 28.89 million shares have been available to trade. The percentage of shares being held by the company management was 0.9% while institutions stake was 34.7%. The company has generated negative returns on equity over the last 12 months (-38.6%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the NLNK stock, there is another set of technicals that should be looked into and considered. Its -6.72% decline from moving average of $1.68 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.5 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of NewLink Genetics Corporation — 0 analysts rate the stock as a buy with another 0 rating it strong buy. There are 2 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $4.3333 on shares of NewLink Genetics Corporation (NASDAQ:NLNK), which corresponds to 174.26% upside potential than its current market price of $1.57 and implies potential despite the recent drop in the price. However, their current target price has fallen from $4.3333 a month ago and is down handily from the consensus target of $5 a quarter ago.
In the last five years, the EPS of the company has been roughly -3.2%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 15.2%. The revenue of the company has risen at an average annualized rate of about 62.7 over the last five years. The company recently recorded a drop of -99%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards NLNK stock. Morgan Stanley added position in the company after it grew 307.9% or 17,472 shares of its common stock. The hedge fund now owns 71,270 shares worth $111,894, SEC documents show. Oxford Asset Management LLP cut assets in the stock as 728863.1 shares have been sold, reducing its stake by -35% to 473,761 shares which are currently valued at $743,805. In addition, Renaissance Technologies LLC recently reported that it now owns 2,721,813 shares making a total of $4,273,246 based on the recent price. This refelects a change of 19.5% in their ownership.